Neutralizing antibodies to HIV-1 and their use

Patent metadata

Field	Value
Publication number	US-9738703-B2
Application number	US-201514864705-A
Country	US
Kind code	B2
Filing date	Sep 24, 2015
Priority date	Sep 25, 2009
Publication date	Aug 22, 2017
Grant date	Aug 22, 2017

Abstract

Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.

First claim

We claim:

1. A method of treating a human immunodeficiency virus (HIV)-1 infection in a subject or inhibiting infection of a subject with HIV-1, comprising:
administering to the subject a therapeutically effective amount of an antibody or a functional fragment thereof comprising:
a heavy chain variable region comprising a heavy chain complementarity determining region (HCDR) 1, a HCDR2, and a HCDR3, comprising amino acids 26-33, 51-58, and 97-110, of SEQ ID NO: 1, respectively; and
a light chain variable region comprising a light chain complementarity determining region (LCDR) 1, a LCDR2, and a LCDR3, comprising amino acids 27-30, 48-50, and 87-91, of SEQ ID NO: 2, respectively; and
wherein the antibody or the functional fragment specifically binds to gp120, thereby treating the HIV-1 infection in the subject or inhibiting infection of the subject with HIV-1.

2. The method of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 1.

3. The method of claim 1 , wherein the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 2.

4. The method of claim 1 , wherein:
the heavy chain variable region comprises the HCDR1, the HCDR2, and the HCDR3, and an amino acid sequence at least 90% identical to the amino acid sequence set forth as SEQ ID NO: 1; and
the light chain variable region comprises the LCDR1, the LCDR2, and the LCDR3, and an amino acid sequence at least 90% identical to the amino acid sequence set forth as SEQ ID NO: 2.

5. The method of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 1, and the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 2.

6. The method of claim 1 , wherein the antibody is an IgG, an IgM, or an IgA.

7. The method of claim 1 , wherein the antibody is an IgG1.

8. The method of claim 1 , wherein the fragment is a Fab fragment, a Fab′ fragment, a F(ab)′ 2 fragment, a single chain Fv protein (scFv), or a disulfide stabilized Fv protein (dsFv).

9. The method of claim 8 , wherein the fragment is a Fab fragment.

10. The method of claim 1 , wherein the method comprises treating the HIV-1 infection and the subject is infected with HIV-1.

11. The method of claim 1 , wherein the method comprises treating the HIV-1 infection and the subject has acquired immune deficiency syndrome (AIDS).

12. The method of claim 1 , wherein the method comprises inhibiting infection of the subject with HIV-1 and the subject is at risk of infection with HIV-1.

13. The method of claim 1 , wherein the subject is pregnant.

14. The method of claim 1 , wherein the subject is a breastfeeding mother.

15. The method of claim 1 , wherein the subject is an infant.

16. The method of claim 1 , wherein the administration is an intravenous administration or a subcutaneous administration.

17. The method of claim 1 , further comprising administering to the subject an anti-viral agent.

18. A method for treating a human immunodeficiency virus (HIV)-1 infection in a subject or inhibiting infection of a subject with HIV-1, comprising:
administering to the subject a therapeutically effective amount of an expression vector comprising a nucleic acid molecule encoding an antibody or a functional fragment thereof comprising:
a heavy chain variable region comprising a heavy chain complementarity determining region (HCDR) 1, a HCDR2, and a HCDR3, comprising amino acids 26-33, 51-58, and 97-110, of SEQ ID NO: 1, respectively; and
a light chain variable region comprising a light chain complementarity determining region (LCDR) 1, a LCDR2, and a LCDR3, comprising amino acids 27-30, 48-50, and 87-91, of SEQ ID NO: 2, respectively; and
wherein the antibody or the functional fragment specifically binds to gp120, and wherein expression of the antibody or antigen binding fragment in the subject treats the HIV-1 infection in the subject or inhibiting infection of the subject with HIV-1.

19. The method of claim 18 , wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 1, and the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 2.

20. The method of claim 1 , wherein the heavy chain variable region comprises the HCDR1, the HCDR2, and the HCDR3, and an amino acid sequence at least 90% identical to SEQ ID NO: 1.

21. The method of claim 1 , wherein the light chain variable region comprises an amino acid sequence at least 90% identical to SEQ ID NO: 2.

Assignees

• Us Health
• Univ Washington

Inventors

• Mascola John
• Wyatt Richard
• Wu Xueling
• Li Yuxing
• Hogerkorp Carl-Magnus
• Roederer Mario
• Yang Zhi-Yong
• Nabel Gary
• Kwong Peter
• Zhou Tongqing
• Connors Mark
• Schief William

Classifications

• C12N2740/10011

  Retroviridae · CPC title

• C12N2740/16111

  concerning HIV env · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61P31/18

  for HIV · CPC title